Ratings Waters Corporation

Equities

WAT

US9418481035

Real-time Estimate Cboe BZX Other stock markets 10:06:49 2024-04-23 am EDT			5-day change	1st Jan Change
308.5 ^USD	+3.08%		-2.17%	-6.78%

Apr. 22	Bernstein Adjusts Price Target on Waters to $304 From $307	MT
Apr. 22	Baird Adjusts Price Target on Waters to $319 From $315	MT

Summary

The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's activity appears highly profitable thanks to its outperforming net margins.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

The firm trades with high earnings multiples: 27.09 times its 2024 earnings per share.
The company's "enterprise value to sales" ratio is among the highest in the world.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The company is highly valued given the cash flows generated by its activity.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the past year, analysts have significantly revised downwards their profit estimates.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
WATERS CORPORATION	-6.78%	17.75B	A-
THERMO FISHER SCIENTIFIC	+6.30%	209B	B
DANAHER CORPORATION	+8.74%	175B	B-
INTUITIVE SURGICAL, INC.	+9.91%	131B	B-
BOSTON SCIENTIFIC CORPORATION	+18.34%	99.98B	A-
SIEMENS HEALTHINEERS AG	-0.99%	61.12B	A-
EDWARDS LIFESCIENCES CORPORATION	+14.18%	52.34B	B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-4.15%	46.5B	B+
AGILENT TECHNOLOGIES, INC.	-1.68%	39.24B	A
GE HEALTHCARE TECHNOLOGIES INC.	+10.22%	38.47B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes